Navigation Links
TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
Date:9/30/2010

JERUSALEM, BOTHELL, WA and VANCOUVER, Sept. 30 /PRNewswire-FirstCall/ - Teva Pharmaceuticals Industries Ltd. (NASDAQ: TEVA) and OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC). The SYNERGY trial is the second of three Phase 3 trials to be initiated under a global collaboration and license agreement between Teva and OncoGenex to develop and commercialize custirsen.

The SYNERGY trial is a randomized, controlled, global Phase 3 trial to be conducted in approximately 125 cancer centers and with designated recruitment of 800 men with metastatic CRPC who have disease progression and require first-line docetaxel/prednisone chemotherapy. Patients will be randomized to receive treatment with either docetaxel/prednisone plus custirsen or with docetaxel/prednisone alone. The primary endpoint of the trial is to determine whether overall survival is longer in the custirsen treatment arm. The trial design is based on the Phase 2 trial results demonstrating clinical benefits of custirsen treatment with a hazard ratio consistent with a 49% reduction in the rate of death and a median overall survival of 23.8 months compared to 16.9 months.

The initiation of SATURN, the first Phase 3 trial with custirsen was announced by Teva and OncoGenex in June 2010. This global Phase 3 trial will enrol patients with metastatic CRPC who have previously responded to first line docetaxel/prednisone treatment but subsequently have disease progression that involves pain despite opioid usage.

"The prostate cancer landscape is rapidly evolving with the introduction of new therapies to improve patient outcomes." said Dr.
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
2. OncoGenex Reports Second Quarter Financial Results
3. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
4. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
5. OncoGenex Reports First Quarter Financial Results
6. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
7. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
8. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
9. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
10. OncoGenex Reports Third Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... 18, 2014 Research and Markets ... Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - ... offering. The global companion diagnostics market ... from 2014 to 2019. Factors such as rising need ... companion diagnostics by the pharmaceutical industry, support from regulatory ...
(Date:9/18/2014)... Leatherwood Plastics has selected Vycom’s ... stay competitive in the semiconductor, clean room and ... impact product quality and productivity, according to Dwight ... in 1980 in Lewisville, TX, Leatherwood Plastics ... left the business. Much of Leatherwood’s equipment building ...
(Date:9/18/2014)... -- U.S. biotech company Kultevat has strengthened its ... developed by the Donald Danforth Plant Science Center ... applications in production of natural rubber in Taraxicum ... under the direction of Roger Beachy , Ph.D., ... the Danforth Plant Science Center, and is used to ...
(Date:9/18/2014)... , Sept. 18, 2014  MEI Pharma, Inc. (Nasdaq: ... development of novel therapies for cancer, announced today that ... will present at BioCentury,s NewsMakers in the Biotech Industry ... Eastern time from the Millennium Broadway Hotel & Conference Center ... of the presentation can be accessed at www.meipharma.com . ...
Breaking Biology Technology:Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3Leatherwood Plastics Selects Vycom’s Flametec PVC-C Material to Stay Competitive in Semiconductor and Lab Equipment Industries 2Kultevat obtains license of gene switch technology 2MEI Pharma To Present At BioCentury's NewsMakers Conference 2MEI Pharma To Present At BioCentury's NewsMakers Conference 3
... class of enzymes routinely used to synthesizing some of nature's ... a new way to expand on nature's chemical creativity to ... (Sept. 1) in the journal Science , a team ... at the University of Wisconsin-Madison , describes the discovery ...
... life sciences company with 120 Madison employees is bolstering ... of proteins in today's drug development market. , ,The ... Corp. 's recent acquisition of Sentigen Holding Corp., which ... Madison. , , The scientific opportunity , ,The ...
... summer, but for workers the lazy, hazy, crazy vacation days ... So now that we are all rested and relaxed, what ... , ,Well, actually neither workers or the workplace seem to ... conflict and strife between management and workers, real tensions exist ...
Cached Biology Technology:UW finds new path to anti-cancer agents 2UW finds new path to anti-cancer agents 3Invitrogen boosts drug development capability 2Workplace flexibility: Give and take or tug of war? 2Workplace flexibility: Give and take or tug of war? 3Workplace flexibility: Give and take or tug of war? 4Workplace flexibility: Give and take or tug of war? 5
(Date:9/18/2014)... Va.Sept. 18, 2014Many Americans across racial and ethnic ... greatest impact on their day-to-day life, more so ... hearing and speech (57% of African-Americans, 49% of ... Hispanics). When asked which disease or ailment is ... ranked first among African-Americans followed by AIDS/HIV. ...
(Date:9/18/2014)... characters, so you might expect that most would have ... some dogs are distinctly more pessimistic than others, research ... research is exciting because it measures positive and negative ... researchers and dog owners an insight into the outlook ... Starling, from the Faculty of Veterinary Science. Her PhD ...
(Date:9/18/2014)... from several disciplines will be celebrated tonight at the ... in improving the health of premature infants and in ... The researchers, whose work was supported by the National ... former Atomic Energy Commission, will be honored at a ... A bipartisan group of Members of Congress will be ...
Breaking Biology News(10 mins):Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3Dogs can be pessimists too 2Dogs can be pessimists too 33rd annual Golden Goose award ceremony honors 8 researchers; Unusual work had big results 2
... Nov. 18, 2010 The 2010 Golf Atlanta charity golf ... aimed at finding better treatments and eventually a cure for ... 15, 2010, to the Crabapple Golf Club in Alpharetta, Ga., ... Genomics Research Institute (TGen), a non-profit biomedical research facility in ...
... For Immediate Release While scientists depend on ... long and frequently frustrating process. For one Scripps Research ... Ja, an assistant professor in the Department of Metabolism ... January, was recently awarded an unsolicited grant of $60,000 ...
... November 18, 2010 The Paul G. Allen Family ... and cellular engineering research. The Allen Distinguished Investigator Awards ... Washington, California, Massachusetts and New York. The grants ... years. "A year ago, I started ...
Cached Biology News:Golf Atlanta charity tournament raises $105,000 for TGen research 2New Scripps Florida scientist awarded pair of unconventional grants 2First Allen Distinguished Investigators named 2First Allen Distinguished Investigators named 3
... 2000 instrument can be used as a ... Data Manager Software provides the means to ... the instrument. These data can then be ... such as Microsoft Excel or Lotus 123, ...
... Gasket slide kit (1x 22K gasket/slide) G2534-60003 ... or Gasket slide kit (2x 11K ... slides offered in either 11K or 22K microarray feature ... gaskets are carefully fabricated and batch tested to ensure ...
... is a new product number, ... product number. If showing no ... the old Sigma-Aldrich number (Z71,346-5) ... assistance. ID clarifier: box holds ...
... description: self locking design in ice/water ... new product number, created to easily ... no availability yet, please order under ... contact customer service for assistance. ID ...
Biology Products: